Hoth Therapeutics Inc
HOTH1.090USD
+0.020+1.87%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
16.49MMarket Cap
LossP/E TTM
More Details of Hoth Therapeutics Inc Company
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Hoth Therapeutics Inc Info
Ticker SymbolHOTH
Company nameHoth Therapeutics Inc
IPO dateFeb 15, 2019
CEOKnie (Robb)
Number of employees2
Security typeOrdinary Share
Fiscal year-endFeb 15
Address1177 Avenue Of The Americas
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone16467562997
Websitehttps://hoththerapeutics.com/
Ticker SymbolHOTH
IPO dateFeb 15, 2019
CEOKnie (Robb)
Company Executives of Hoth Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
5.08K
--
Mr. Wayne Linsley
Mr. Wayne Linsley
Independent Director
Independent Director
134.00
--
Mr. David S. Briones
Mr. David S. Briones
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David Sarnoff
Mr. David Sarnoff
Independent Director
Independent Director
--
--
Mr. Robb Knie
Mr. Robb Knie
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Camarra
Mr. Chris Camarra
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
5.08K
--
Mr. Wayne Linsley
Mr. Wayne Linsley
Independent Director
Independent Director
134.00
--
Mr. David S. Briones
Mr. David S. Briones
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David Sarnoff
Mr. David Sarnoff
Independent Director
Independent Director
--
--
Mr. Robb Knie
Mr. Robb Knie
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Camarra
Mr. Chris Camarra
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Knie Robb
3.53%
Renaissance Technologies LLC
1.57%
The Vanguard Group, Inc.
1.38%
Geode Capital Management, L.L.C.
0.99%
Citadel Advisors LLC
0.92%
Other
91.61%
Shareholders
Shareholders
Proportion
Knie Robb
3.53%
Renaissance Technologies LLC
1.57%
The Vanguard Group, Inc.
1.38%
Geode Capital Management, L.L.C.
0.99%
Citadel Advisors LLC
0.92%
Other
91.61%
Shareholder Types
Shareholders
Proportion
Individual Investor
3.57%
Investment Advisor
2.84%
Hedge Fund
2.82%
Investment Advisor/Hedge Fund
1.79%
Research Firm
1.16%
Other
87.82%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
31
425.61K
3.21%
-98.63K
2025Q2
38
380.38K
2.88%
-195.26K
2025Q1
40
372.42K
2.82%
-225.56K
2024Q4
39
309.11K
4.48%
-429.76K
2024Q3
42
431.69K
6.25%
-86.29K
2024Q2
42
388.94K
7.91%
-315.12K
2024Q1
44
566.05K
12.84%
+79.22K
2023Q4
44
349.12K
8.32%
+102.75K
2023Q3
49
137.03K
3.75%
-357.00K
2023Q2
50
112.35K
3.42%
-337.54K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Knie Robb
547.39K
4.13%
+489.26K
+841.64%
Aug 28, 2025
The Vanguard Group, Inc.
38.80K
0.29%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
122.58K
0.92%
+9.07K
+7.99%
Jun 30, 2025
UBS Financial Services, Inc.
42.24K
0.32%
-16.52K
-28.11%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 25, 2022
Merger
25→1
Oct 25, 2022
Merger
25→1
Oct 25, 2022
Merger
25→1
Oct 25, 2022
Merger
25→1
Date
Type
Ratio
Oct 25, 2022
Merger
25→1
Oct 25, 2022
Merger
25→1
Oct 25, 2022
Merger
25→1
Oct 25, 2022
Merger
25→1
FAQs
Who are the top five shareholders of Hoth Therapeutics Inc?
The top five shareholders of Hoth Therapeutics Inc are:
Knie Robb holds 547.39K shares, accounting for 4.13% of the total shares.
The Vanguard Group, Inc. holds 38.80K shares, accounting for 0.29% of the total shares.
Geode Capital Management, L.L.C. holds 122.58K shares, accounting for 0.92% of the total shares.
UBS Financial Services, Inc. holds 42.24K shares, accounting for 0.32% of the total shares.
Knie Robb holds 547.39K shares, accounting for 4.13% of the total shares.
The Vanguard Group, Inc. holds 38.80K shares, accounting for 0.29% of the total shares.
Geode Capital Management, L.L.C. holds 122.58K shares, accounting for 0.92% of the total shares.
UBS Financial Services, Inc. holds 42.24K shares, accounting for 0.32% of the total shares.
What are the top three shareholder types of Hoth Therapeutics Inc?
The top three shareholder types of Hoth Therapeutics Inc are:
Knie Robb
Renaissance Technologies LLC
The Vanguard Group, Inc.
Knie Robb
Renaissance Technologies LLC
The Vanguard Group, Inc.
How many institutions hold shares of Hoth Therapeutics Inc (HOTH)?
As of 2025Q3, 31 institutions hold shares of Hoth Therapeutics Inc, with a combined market value of approximately 425.61K, accounting for 3.21% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.33%.
What is the biggest source of revenue for Hoth Therapeutics Inc?
In --, the -- business generated the highest revenue for Hoth Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
